Profound Medical Corp. PROF

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
49/100
Developing

Ranked against 159 peers in Medical Devices

About Profound Medical Corp.

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to … Full PROF analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.81). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.88). Margin expansion confirms commercial leverage is building.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.37). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.24). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
52
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where PROF ranks in Medical Devices

Profound Medical Corp. ranks #78 of 160 scored companies in Medical Devices by moat score — the top 49%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
74 Quantum-Si Incorporated QSI 49/100 Developing
75 Quantum-Si incorporated QSIAW 49/100 Developing
76 Owlet, Inc. OWLT 49/100 Developing
77 CVRx, Inc. CVRX 49/100 Developing
78 Profound Medical Corp. PROF 49/100 Developing
79 Butterfly Network, Inc. BFLY 49/100 Developing
80 Accuray Incorporated ARAY 49/100 Developing
81 Tandem Diabetes Care, Inc. TNDM 49/100 Developing
82 DIH Holding US, Inc. DHAI 48/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How PROF scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 52 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 42 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 50 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 51 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 40 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 66 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding PROF's moat

What is Profound Medical Corp.'s moat score?

Profound Medical Corp. (PROF) scores 49 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #78 of 160 scored companies in Medical Devices, the top 49%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Growth Durability (66/100) and its weakest is Capital Structure & Resilience (40/100).

How does Profound Medical Corp. compare with other Medical Devices companies?

Profound Medical Corp. ranks #78 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are CVRx, Inc. (CVRX) at 49 just above it and Butterfly Network, Inc. (BFLY) at 49 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Profound Medical Corp. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Profound Medical Corp.?

The Medical Devices & Diagnostics template measures 6 defenses, and PROF scores: Pricing Power & Consumable Moat (52), R&D Pipeline & Capital Returns (42), FCF Quality & Cash Conversion (50), Commercial Execution (51), Capital Structure & Resilience (40), Growth Durability (66). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000